Hematology Frontier

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health priorities. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Zhijian Xiao from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into recent advances in precision risk stratification for myelodysplastic syndromes (MDS) and emerging targeted and immunotherapeutic strategies, highlighting the growing clinical importance of molecular classification in treatment decision-making.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into breakthroughs in FLT3 and IDH1/2 targeted therapy, precision strategies for elderly and high-risk AML populations, and MRD-guided dynamic treatment approaches, offering valuable perspectives for clinical practice and translational research.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA), with a focus on long-term outcomes of haploidentical transplantation, as well as optimization of transplant timing, patient stratification, and donor selection.

As an emerging modality of hematopoietic stem cell transplantation, umbilical cord blood transplantation (UCBT) has demonstrated unique clinical value in the treatment of various hematologic diseases. From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading hematology experts from China and abroad to explore cutting-edge research and national health priorities. During the conference, Professor Zimin Sun from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared in-depth insights into the current clinical status, technical advantages, and evolving research landscape of UCBT.

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the meeting, Professor Wei Xu from Jiangsu Provincial People’s Hospital provided a comprehensive review of key advances in CLL treatment, therapeutic decision-making in high-risk disease, and future research directions, offering valuable insights for optimizing clinical practice.

As a new year begins, global leaders in hematology gathered in Tianjin from January 9–11, 2026, for the 6th China Hematology Discipline Development Conference (CASH). This year’s congress introduced its first-ever International Forum, establishing a new bridge for in-depth dialogue between Chinese and global hematology communities. As one of the Forum Chairs, Professor Toshio Suda of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, brings both international perspective and profound academic influence to the field. Oncology Frontier – Hematology Frontier invited Professor Suda to share the vision behind launching the International Forum, reflect on its key highlights and collaborative achievements, and offer strategic insights on strengthening China’s integration into the global hematology landscape, further advancing international scientific exchange.

The 2025 American Society of Hematology (ASH) Annual Meeting recently concluded in Orlando, USA, showcasing major breakthroughs in lymphoma research and offering new directions for optimizing clinical care. To translate cutting-edge science into clinical insight, Oncology Frontier – Hematology Frontier partners with Professor Qingqing Cai of Sun Yat-sen University Cancer Center to present the “Lymphoma Insights – ASH Special” series, delivering authoritative interpretation of landmark lymphoma studies with practical clinical relevance.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held in Tianjin. The meeting brought together leading international and national experts in hematology, focusing on frontier scientific advances and national health priorities, fostering deep academic exchange and shaping future directions of the discipline.

As the new year begins, leading experts gathered in Tianjin. From  January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held, bringing together top hematology specialists from China and abroad. The conference focused on cutting-edge scientific progress and national health priorities, fostering in-depth discussions on the future of hematology.